Literature DB >> 12626209

WISDOM: history and early demise - was it inevitable?

M Vickers1, T Meade, J Darbyshire.   

Abstract

In 1989, the UK Medical Research Council (MRC) agreed that, if feasible, a randomized controlled trial to assess the long-term risks and benefits of hormone replacement therapy (HRT) was a priority. Feasibility work began in 1990 and demonstrated that a large-scale multicenter trial was possible. An application for funding for a main trial was submitted to MRC in 1993 and, after extensive review, funding was released in late 1996. Set-up work for the trial - the Women's International Study of long Duration Oestrogen after Menopause (WISDOM) - began in 1997 with recruitment in 1999. In October 2002, following the early discontinuation of one arm of the US Women's Health Initiative HRT trial, the MRC decided to stop the WISDOM trial. This article, by the principal UK investigators of WISDOM, sets out the background and history of the trial.

Entities:  

Mesh:

Year:  2002        PMID: 12626209

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  6 in total

1.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

2.  Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort.

Authors:  Gita Mishra; Helen Kok; Russell Ecob; Rachel Cooper; Rebecca Hardy; Diana Kuh
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

3.  Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial.

Authors:  Sirpa-Liisa Hovi; Piret Veerus; Mati Rahu; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2008-08-01       Impact factor: 4.615

4.  The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial.

Authors:  Madge R Vickers; Jeannett Martin; Tom W Meade
Journal:  BMC Womens Health       Date:  2007-02-26       Impact factor: 2.809

5.  Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.

Authors:  Madge R Vickers; Alastair H MacLennan; Beverley Lawton; Deborah Ford; Jeannett Martin; Sarah K Meredith; Bianca L DeStavola; Sally Rose; Anthony Dowell; Helen C Wilkes; Janet H Darbyshire; Tom W Meade
Journal:  BMJ       Date:  2007-07-11

6.  Health related quality of life after combined hormone replacement therapy: randomised controlled trial.

Authors:  Amanda J Welton; Madge R Vickers; Joseph Kim; Deborah Ford; Beverley A Lawton; Alastair H MacLennan; Sarah K Meredith; Jeannett Martin; Tom W Meade
Journal:  BMJ       Date:  2008-08-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.